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Background: Persons with a mental health diagnosis have high rates of tobacco use and face numerous barriers to
cessation including high levels of nicotine dependence, low rates of tobacco treatment referrals from mental health
providers, and limited availability of tobacco treatment targeted to their needs. This manuscript describes the
rationale and methods of a clinical trial with the following aims: 1) Compare the reach and efficacy of a proactive
telephone-based tobacco cessation program for Veterans Health Administration (VHA) mental health clinic
patients to VHA usual care and 2) Model longitudinal associations between baseline patient characteristics and
long-term abstinence.
Methods/design: We will use the electronic medical record to identify patients across four VHA healthcare facilities
who have a clinical reminder code indicating current tobacco use in the past six months and who have had a mental
health clinic visit in the past 12 months. We will send each patient an introductory letter and baseline survey. Survey
respondents (N = 3840) will be randomized in a 1:1 fashion to intervention or control. Control participants will receive
VHA usual care. Intervention participants will receive proactive motivational telephone outreach to offer tobacco
treatment. Intervention participants interested in treatment will receive eight weeks of nicotine replacement therapy
plus eight sessions of specialized telephone counseling over two months, followed by monthly maintenance
counseling for four months. We will conduct telephone surveys with participants at six and 12 months to assess study
outcomes. We will collect a mailed saliva sample from patients reporting 7-day abstinence on the telephone surveys.
The primary outcome will be cotinine-validated abstinence at 12-month follow-up.
Discussion: Mental health patients are a high-risk smoking population with significant barriers to cessation. This study
will evaluate the efficacy of a program that proactively reaches out to smokers with a mental health treatment history
to engage them into telephone cessation counseling targeted to the needs of mental health patients.
Trial registration: Clinicaltrials.gov: NCT01737281 (registered November 5, 2012).
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Despite considerable progress, smoking remains the leading
preventable cause of death in the United States, responsible
for over 480,000 deaths and $157 billion in health-related
economic losses each year [1]. Persons with a mental health
diagnosis (DSM-IV, Axis I or II) have particularly high rates
of tobacco use and consume over 46% of cigarettes sold in
the United States per year [2,3]. Patients with bipolar dis-
order or schizophrenia have the highest smoking rates
(69% and 58-90%, respectively) followed by those with post-
traumatic stress disorder (PTSD; 45-63%) and depression
(31-51%) [3-5].
Most mental health patients who smoke are interested in
quitting [6-9]. Smokers with a mental health history face a
number of unique barriers that increase the difficulty of
quitting, namely higher nicotine dependency, shared eti-
ology between smoking and mental health concerns, and
greater susceptibility to relapse [10]. Nicotine can increase
arousal, working memory, and executive functioning,
which could lead to self-medication among some popula-
tions, especially those with schizophrenia, who experience
particular limitations in these areas [11-13]. Higher anxiety
sensitivity and negative affect avoidance may contribute to
the higher relapse rates even among those who initially
quit [14]. Thus, smokers with a mental health history may
require specialized treatment with a focus on behavioral
and affect management. In addition, current evidence sug-
gests that increasing length of tobacco treatment follow-up
may be important for preventing relapse in mental health
populations [15,16].
Even when effective tobacco treatment exists, mental
health patients face barriers to accessing treatment includ-
ing limited support and tobacco treatment from providers
[17-20]. While physicians often assess tobacco use in men-
tal health patients, they rarely follow-up with treatment
[17]. For example, from 2006–2010 60% of outpatient
psychiatry visits in the United States included tobacco
screening, but psychiatrists provided tobacco cessation
counseling during only 23% of visits with smokers [19]. Of
particular concern is that during this same time period psy-
chiatrists prescribed nicotine replacement therapy (NRT)
during less than 1% of visits with smokers. New strategies
are needed to increase access to effective tobacco cessation
treatments among mental health populations.
To overcome access barriers and to better meet the
needs of tobacco-dependent mental health patients, we
have designed and initiated a patient-randomized con-
trolled trial that adapts a program that was previously
found to be effective at increasing access to tobacco
treatment and population-level abstinence among
smokers using Veterans Health Administration (VHA)
primary care clinics [21]. The trial will test the efficacy
of proactively reaching out to VHA mental health pa-
tients who smoke to enroll them in telephone-basedcounseling targeted to the needs of smokers with a men-
tal health history. The trial has two primary aims: (1)
Compare the reach and efficacy of a proactive outreach
telephone-based tobacco cessation program for patients
seen in mental health to usual care advice and referral to
local VHA and community tobacco cessation resources
and (2) Model longitudinal associations between baseline
sociodemographic, medical and mental health characteris-
tics and abstinence at six and 12 months. We hypothesize
that the proactive intervention will increase the proportion
of smokers who are abstinent at 12 month follow-up and
that mental health distress and active substance abuse will




Figure 1 provides an overview of our study design. We
will use the VA’s electronic medical record (EMR) system
to identify a cohort of patients across four VHA health
care facilities who have a clinical reminder health factor
indicating tobacco use in the past six months [22] and
who have had a mental health clinic visit in the past 12
months. We will send each patient an introductory letter
and baseline survey. Current smokers who return a
baseline survey and meet eligibility criteria (target N =
3840) will be randomized in a 1:1 fashion to intervention
or control, stratified by site. Control participants will re-
ceive a mailed list of local VHA smoking cessation treat-
ment options that they can access on their own or to
which they can be referred by their regular VHA pro-
viders (i.e., usual care). Intervention participants will re-
ceive a telephone outreach call to enhance motivation
and provide encouragement to start tobacco cessation
treatment. Intervention participants who are interested
in treatment will receive eight proactive telephone coun-
seling sessions over two months followed by monthly re-
lapse prevention sessions for four months. Intervention
counselors will arrange for Intervention participants to re-
ceive eight weeks of NRT from one of their regular VHA
providers, and they will update Intervention participants’
regular VHA mental health providers on their patients’
progress in tobacco treatment via EMR progress notes.
Research assistants will conduct telephone surveys with
participants at six and 12 months to assess study out-
comes. Research assistants will also collect a mailed saliva
sample from patients reporting 7-day smoking abstinence
on the telephone surveys. The primary outcome is
cotinine-validated abstinence at 12-month follow-up.
Settings
This study will take place at four VHA facilities chosen
to increase generalizability of findings by studying the
intervention in four geographically and culturally diverse
Figure 1 Study overview.
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the VA Minneapolis Healthcare System, the Michael E.
DeBakey VA Medical Center in Houston, Texas and the
James A. Haley Veterans’ Hospital in Tampa, Florida.
The research activities taking place at participating sites
were approved by the VHA Central Institutional Review
Board (protocol #12-42) and each site’s Research and
Development Committee.
Identifying potential participants
Using a three-step process, we will identify potential par-
ticipants using specific combinations of administrative
data contained in the EMR system:
1. Selecting current smokers: Current smokers will be
identified using EMR tobacco use clinical reminder
codes, where information is stored as a health factor.
Patients will be included if they have screened
positive for tobacco use in the previous six months.We selected six months to reduce the false-positive
rate of this sampling method. Patients will be
excluded if they have an ICD 9 diagnosis of
dementia (i.e., 290.XX or 331.XX).
2. Identifying Mental Health patients: Within the list of
all eligible smokers, VHA programmers will identify
patients treated in the previous 12 months in a VHA
Mental Health Clinic, using VHA clinic stop codes:
502–581.
3. Selecting the initial sample: After receiving a list for
each site of current smokers with a recent Mental
Health visit, we will select all women and a random
sample of men to total 1,600 potential participants
from each site (N = 6,400) as our initial recruitment
pool. We are selecting all women to increase the
representation of women in our final sample. Since
we will mail enrollment materials in batches each
month during an 18-moth recruitment period, we
will verify our list of eligible patients each month to
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EMR at the time of enrollment. Each patient who is
no longer listed as a current smoker will be replaced
by another patient from the site prior to enrollment
and randomization.
Inclusion/exclusion criteria
Using administrative data and the baseline survey, we
will verify the study’s inclusion and exclusion criteria
with each potential participant. Anyone who is found to
be ineligible will be excluded prior to randomization and
replaced with a randomly selected person from the list
of current smokers for that particular site. To maximize
reach and impact we have chosen broad inclusion cri-
teria. Inclusion criteria include: (1) Current smoker (i.e.,
any cigarette use in past 30 days) and (2) Mental Health
clinic visit in past 12 months. Exclusion criteria include:
(1) ICD 9 diagnosis of dementia (excluded during data
abstraction process), (2) Does not speak English, and (3)
Does not have telephone and mailing address.
Participant recruitment
We will use a modified Dillman protocol to maximize
recruitment response rates and data quality [23]. First,
we will send each patient a letter from the Chief of Staff,
facility Behavioral Health Coordinator or other compar-
able leader from the facility stating the patients will soon
be contacted about a smoking cessation research study
with the goal of helping Veterans who use VHA mental
health clinics stop smoking. The letter will also include
information on how to contact the project director to
opt-out of receiving further study materials or if they
feel they have been contacted in error (e.g., not a current
smoker or have not used mental health services in the
past 12 months). One week later, we will send out a
packet of information to patients, including a cover let-
ter, a sheet of Frequently Asked Questions (FAQ) about
the study that contains all elements of informed consent,
and a self-administered baseline survey. The cover letter
and FAQ sheet will inform potential participants that
they will receive a $10 payment for returning the survey.
Patients who return a mailed baseline survey and meet
eligibility criteria will be enrolled in the study. The study
was granted a waiver of documentation of informed con-
sent by the VHA Central IRB.
Randomization
When study staff receive a baseline survey, they will enter
the patient’s status into a tracking system created for the
study that prompts staff to verify eligibility criteria from
the baseline survey. The tracking system will randomize
eligible participants in a 1:1 fashion, stratified by site, using
a randomization list created by the study’s statistician.
Study research assistants (who conduct participant surveys,collect saliva samples, and complete other tasks such as
mailing participants reimbursements) will remain blind
to randomization during the study. Study counselors
and supervisors will know the randomization status of
each participant.
Intervention group: proactive telephone treatment
Telephone counseling
Within one week of receiving a completed baseline survey,
a counselor will phone participants randomized to the
intervention arm. The counselor will make up to six con-
tact attempts at different times of day to reach partici-
pants. The purpose of the outreach call is to: 1) deliver
motivational enhancement to quit smoking, 2) promote
self-efficacy in quitting, and 3) encourage participants to
participate in smoking cessation treatment. Participants
do not need to engage in counseling to participate in the
study. Participants who engage in counseling will receive
the full telephone counseling protocol which is adapted
from a protocol we previously found to be more effective
with VHA mental health patients than state Quitline
counseling [24]. The protocol is characterized by:
 Motivational enhancement – Guided by a
motivational interviewing (MI) approach, we will
include motivational enhancement in each of the
first several telephone calls and as-needed during
later calls to increase patient motivation to quit and
reduce relapse.
 Multiple sessions – Participants can receive up to 12
counseling calls comprised of eight calls over two
months to help participants make a quit attempt
followed by monthly maintenance call for four months.
 Relapse-sensitive scheduling – Participants will
receive four calls to plan a quit date, three calls in the
first two weeks after their quit date, when the relapse
risk is highest, followed by another call four weeks
after their quit date. Participants will receive monthly
maintenance calls for four months to work through
any slips or barriers to continued abstinence [15,16].
 Problem-solving therapy – This approach, based on
helping the smoker identify and solve expected and
actual challenges, is endorsed by the national
smoking cessation guidelines [25].
 Stress Reduction – The counseling protocol includes
stress reduction techniques, such as relaxation and
mindfulness exercises [26,27], smoking schedules to
remove the link between smoking and stress responses
[28], and stress reduction self-help materials that
counselors will discuss with participants.
Medication requests
All smokers in the intervention arm will be asked about
their NRT preference during the outreach call and first
Table 1 Measures and assessment schedule
Measure Baseline 6 m 12 m
Participant surveys
Eligibility: Smoking in last 30 days X
Sociodemographics X
Smoking and tobacco use history X X X
Nicotine dependence X X X
Quit attempt history X X X
Cessation treatment offered by providers X X X
Texting/social media use and preferences X
Thoughts about quitting X X X
Motivation to quit X X X
Self-efficacy in quitting X X X
Environmental factors X X X
Physical and mental health X X X
Alcohol use X X X
Pain intensity and interference X X X
Financial stress X X X
Smoking-induced deprivation X X X
Participant saliva sample X X
Administrative data
Demographics
Cessation prescriptions in prior 12 months X X
Healthcare utilization in prior 12 months X X
Body mass index in prior 12 months X X
Charlson comorbidity index X
Mental health diagnoses in prior 12 months X
Primary mental health diagnosis X
Mental health diagnostic cluster X
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EMR system for their facility’s smoking cessation program
or the participant’s regular primary care provider indicating
that the participant expressed interest in receiving NRT
and their preference. The alert will also contain relevant in-
formation from the US Public Health Services guidelines
for the treatment of tobacco [25]. The counselors will
monitor the participants’ EMR for whether a prescription
is written. If no prescription is written within one week
after sending the alert, the counselor will place a follow-up
alert reiterating the participant’s expressed interest in NRT.
The regular VHA providers will not be required to pre-
scribe or be required to prescribe the patient’s preferred
NRT. Rather, study counselors will simply notify the pro-
viders that the patient expressed interest in receiving NRT.
Study counselors will also encourage participants to dis-
cuss NRT use with their regular providers.
Engaging mental health providers in the treatment process
In recognizing that a patient’s mental health providers
are an important source of support and treatment en-
couragement for our patient population, we will engage
intervention patients’ primary mental health providers
into the treatment process by alerting the providers of
their patients’ progress via EMR progress notes.
Control group: VHA usual care
We will send smokers randomized to the control group
a mailed list of local VHA and non-VA smoking cessa-
tion services that they can access on their own. In
addition, patients randomized to the control group may
receive treatment or referrals to treatment from their
regular VHA providers as part of usual care. Pharmaco-
therapy is available at all sites in the form of nicotine re-
placement (patches, gum and lozenges) and bupropion.
Measures and data collection
Participant surveys
Table 1 shows the study’s measures and assessment sched-
ule. Participants will be surveyed by mail at baseline. Par-
ticipants will be surveyed by telephone six and 12 months
after the date study staff receive the baseline survey or by
mail if they are not responsive to telephone contacts. Re-
search assistants blinded to randomization will make up
to ten attempts over a 2-month window at different days
and times to reach participants for each follow-up survey.
Patients will receive a $10 payment as reimbursement for
completing each survey.
Baseline Survey – The baseline survey will assess socio-
demographics, smoking habits and history [29], cessation
treatments offered by providers in the prior 12 months,
nicotine dependence [30], quitting stage of change [31],
self-efficacy for smoking cessation, AUDIT-C to assess al-
cohol use [32,33], Kessler-6 scale to assess psychologicaldistress [34], PHQ-8 to assess depressive symptoms [35],
texting and social media preferences for tobacco cessation,
environmental factors toward smoking and quitting, pain
intensity and interference, financial stress, and smoking-
induced deprivation.
Follow-up Surveys - All measures assessed at baseline
will be assessed again at six and 12 months except the
sociodemographic measures and texting/social media
preferences. We will assess cessation outcomes at six and
12 months using recommended guidelines for tobacco
cessation clinical trials [36,37]. We will assess smoking ab-
stinence (7-day point prevalence), quit attempts, reduction
in smoking, and use of cessation pharmacotherapy and
non-pharmacological cessation treatments (including tele-
phone counseling outside of the study).
Participant saliva sample
Self-reported smoking abstinence can be verified by as-
says of cotinine, the principal metabolite of nicotine.
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7-day abstinence from cigarettes. Sample collection will
be conducted by mail. A research assistant will send a
saliva collection kit, collection instructions and a
postage-paid return envelope on the day of telephone
survey. Participants will receive up to three kits and five
reminder calls to return a saliva sample within 30 days
of completing the telephone survey. Participants will re-
ceive a $25 payment for returning a saliva sample.
Administrative data
We will use the EMR to obtain administrative data at
baseline on all patients in the recruitment cohort and at
12 months on all participants. Data will include demo-
graphics (to use when data are missing on the baseline
survey), cessation prescriptions in the prior 12 months,
health care utilization in the prior 12 months, body mass
index in prior 12 months, and diagnoses in the prior 12
months. We will use diagnoses in the chart to calculate
a Charlson Comorbidity Index (CBI) for all participants.
We will assign to each patient a primary mental health
diagnosis using methods recommended by the VHA
Mental Health Quality Enhancement Research Initiative
(MH QUERI). Primary mental health diagnosis will be
defined as the most frequently occurring diagnosis coded
during mental health clinic encounters during the 12
months prior to enrolling in the trial. We will then assign
one of six main diagnostic categories to each participant
based on their primary diagnosis: affective disorders, sub-
stance abuse disorders, non-PTSD anxiety disorders,
PTSD, schizophrenia disorders, or other diagnoses.
Outcomes
The primary outcome will be cotinine-validated abstin-
ence from smoking at 12-month follow-up. Secondary
outcomes will be: (1) Self-reported 7-day abstinence at
six and 12 month follow-up and six-month prolonged
abstinence at 12 month follow-up, (2) Other cessation
related outcomes at six and 12 months – e.g., quit at-
tempts, cigarettes per day, cessation medication use, mo-
tivation, and self-efficacy, and (3) Self-reported mental
health distress and active substance abuse.
Data analysis
Aim 1 Analysis – Intervention Reach: We will assess the
reach of proactive tobacco treatment in a VHA mental
health population using two indices. First, we will calcu-
late the proportion of patients in our recruitment cohort
who respond to outreach materials and enroll in the
study. This will help us understand the effectiveness of
using the EMR to create a registry of smokers using
VHA mental health clinics who will respond to proactive
outreach. In addition, using administrative data collected
on all patients in our recruitment cohort, we will uselogistic regression to determine which characteristics (e.g.,
age, race/ethnicity, primary mental health diagnosis) are
associated with response to proactive outreach. Second,
among enrolled participants we will compare the two study
arms on the proportion of participants who report using
tobacco treatment (telephone counseling and/or medica-
tions) on follow-up surveys. We will use logistic regression
to determine which characteristics from the baseline sur-
veys are associated with use of telephone counseling and
medications in the two study arms.
Aim 1 Analysis – Intervention Efficacy: The primary out-
come for this analysis will be dichotomous cotinine-
validated abstinence (cotinine <15 ng/ml) at 12 months
post-enrollment [38]. The comparisons of the abstinence
rates across the two groups will be made using exact logis-
tic regression methods, accounting for stratification by site.
Aim 2 Analysis - Modeling Longitudinal Abstinence:
We will use a generalized linear mixed model approach
[39] to model abstinence at six and 12 months. Follow-
ing recommended best practices in longitudinal data
analysis [40], we will use a two-level hierarchical linear
model to fit the data. The outcome variable of interest
will be dichotomous cotinine-validated smoking abstin-
ence. Therefore, a logit mixed model with intercept, time
and time by intervention effects being random (varying
across individuals), while the intervention is treated as a
fixed effect. This longitudinal analytic approach will help
understand to what extent treatment effects differ between
six and 12 months and whether they show a delayed effect
(either increasing or decreasing over time) to determine a
treatment main effect as well as a treatment by time inter-
action. Since this is a randomized experiment across the
treatment arms, no covariate adjustments is needed. How-
ever, in the cases that randomization is not successful to
provide balance, imbalanced baseline covariates will be in-
cluded at the patient level (e.g., age, sex, race/ethnicity,
nicotine dependence, motivation, self-efficacy, mental dis-
tress, and current substance use).
Missing data
We anticipate low, but potentially important rates of sur-
vey non-response to all or part of the 6- and 12-month
surveys. We will use the evidence-based recruitment strat-
egies described above (reimbursements, reminders, mixed
mode survey administration) to minimize non-response.
A common practice in smoking cessation research is to
treat non-respondents at follow-up as continuing smokers
(i.e., intent to treat). This practice is perceived to be a con-
servative approach but does not produce valid estimates
of quit rates [41]. Therefore, we will use multiple imputa-
tions to fully use available baseline information and partial
later surveys. We will use a propensity-based multiple im-
putation method similar to that discussed by Little [42]
using separate imputation procedures within each study
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combination, we will estimate the propensity for respond-
ing to cotinine validated abstinence for each individual
from a logistic regression model for survey response using
the characteristics measured at baseline as explanatory
measures. Within a combination of intervention and design
strata, we will further stratify the sample according to the
values for these estimated propensities. Within a propensity
substratum, we will impute a value for the outcome meas-
ure for each non-respondent by randomly sampling an out-
come value from the respondent values in the substratum.
Multiple completed datasets will be created and the point
estimates and the estimated standard error from each data-
set will be combined to arrive at a single point estimate
(using the specific method discussed below), its estimated
standard error, and the associated confidence interval or
significance test. This approach assumes that missing out-
come data due to non-response is missing at random.
To assess the impact of non-ignorable survey non-
response, or missing not at random non-response, we will
implement pattern-mixture analyses. Using content expert-
ise and the observed missing data patterns, we will develop
these pattern-mixture models. The nature of these models
is difficult to specify in advance of observing the different
patterns but we will posit distributions for the missing data.
For each set of posited distributions and the observed data,
we will calculate revised estimates for the relevant inter-
vention effects. One potential model would be to use the
propensity stratum derived in the analysis described above
and, within each stratum build a distribution for the out-
come of interest by shifting the observed distribution
among the responders. Content expertise and empirical re-
sults will be used to determine the form and magnitude of
shift. These distributions would then be used to impute
values for the non-responders to cotinine validation in the
imputation process described immediately above. Varia-
tions of this approach and other approaches will be used to
assess the sensitivity of the analyses above to non-ignorable
non-response.
Power calculation
The power analysis is based on the primary outcome –
cotinine-validated abstinence at 12-month follow-up. Our
data are stratified on four hospital sites. Considering that a
stratified random sample is usually more efficient than a
simple random sample, we assume the two groups are two
independent simple random samples. We estimate the quit
rate in the control group will be 4%. In the intervention
group, we estimate that about 20% of participants will use
telephone counseling and that the quit rate among Vet-
erans enrolled in counseling will be 16%. When the treat-
ment cessation rate is combined with that from patients
who do not accept treatment (assuming also a 4% quit
rate), there will be a population-level quit rate of 6.4% inthe intervention group. A sample size of 3840 (N= 1920
per arm) provides 80% power to detect any increase greater
than 2.0% in population-level abstinence rate for the inter-
vention group when the abstinence rate in the control
group is 4%, a small but clinically-meaningful quit rate that
results in overall cost-savings [43].
Discussion
Persons with a mental health diagnosis use tobacco at
alarming rates, which has a large negative impact on
their health and quality of life. Their increased vulner-
abilities to tobacco dependence, high risk for relapse,
and difficulties in accessing tobacco treatment make
them an important population to target with tobacco
cessation interventions. The present study examines the
feasibility of an innovative health care delivery model de-
signed to overcome barriers to care and maximize the
utility of the electronic health records to target effective
tobacco cessation treatment to the entire population of
mental health smokers in four VHA healthcare systems.
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